Sight Sciences (SGHT) EBITDA Margin (2020 - 2026)

Sight Sciences' EBITDA Margin history runs 7 years deep, the most recent figure standing at 63.02% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 1614.0% year-over-year to 63.02%; the TTM figure through Mar 2026 stood at 8.32% (up 5526.0% YoY), while the FY2025 annual figure was 10.43%, up 5284.0% from the prior year.
• EBITDA Margin was 63.02% for Q1 2026 at Sight Sciences, down from 124.42% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 124.42% in Q4 2025 to a low of 149.14% in Q1 2022.
• Historically, EBITDA Margin has averaged 66.89% across 5 years, with a median of 64.71% in 2023.
• The sharpest annual moves came in 2022 and 2025: EBITDA Margin slumped 4435 bps in 2022, then surged 18696 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 83.01% in 2022, then rose by 29 bps to 59.25% in 2023, then fell by 6 bps to 62.54% in 2024, then soared by 299 bps to 124.42% in 2025, then plunged by 151 bps to 63.02% in 2026.
• The last three EBITDA Margin figures came in at 63.02% (Q1 2026), 124.42% (Q4 2025), and 39.71% (Q3 2025), per Business Quant data.